Literature DB >> 15087298

Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension.

Hanno H Leuchte1, Claus Neurohr, Rainer Baumgartner, Michael Holzapfel, Wolfgang Giehrl, Michael Vogeser, Jürgen Behr.   

Abstract

Pulmonary hypertension (PH) can develop in lung fibrosis, and contributes to increased morbidity and mortality. Noninvasive parameters in the evaluation of PH in lung disease could aid in the management of these subjects. In this study, we aimed to characterize the role of brain natriuretic peptide (BNP) and the six-minute walk distance (6-MWD) in the assessment of pulmonary hypertension (PH) in subjects with lung fibrosis. Subjects with lung fibrosis and elevated BNP levels (n = 20) had significantly more severe PH during right heart catheterization than those with lung fibrosis, and normal BNP levels (mean pulmonary arterial pressure (40.85 +/- 3.2 mm Hg vs. 23.42+/-1.44 mm Hg, respectively) (n = 19) (p < 0.001). Significant correlations between lung volumes and BNP concentrations were not observed. A weak correlation existed between capillary pO(2) and 6-MWD (r = 0.42; p < 0.001). The presence of moderate-severe PH was associated with significant reduction of the 6-MWD. BNP concentrations predicted moderate-severe PH with 100% sensitivity and high specificity (89%). We conclude that BNP is an excellent marker for the presence of PH in patients with lung fibrosis. In addition, our data suggest that PH contributes significantly to exercise limitation in patients with severe lung fibrosis, raising the possibility that treatment of PH may be beneficial in these patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15087298     DOI: 10.1164/rccm.200308-1142OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  33 in total

1.  Prediction of pulmonary hypertension in idiopathic pulmonary fibrosis.

Authors:  David A Zisman; David J Ross; John A Belperio; Rajan Saggar; Joseph P Lynch; Abbas Ardehali; Arun S Karlamangla
Journal:  Respir Med       Date:  2007-07-02       Impact factor: 3.415

2.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

3.  Cardiac Effect of Interstitial Lung Disease Correlated with Spirometry and Six Minute Walk Test.

Authors:  Mitali Bharat Agrawal; Nilkanth Tukaram Awad
Journal:  J Clin Diagn Res       Date:  2017-02-01

4.  Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension.

Authors:  Roberto F Machado; Sabrina Martyr; Gregory J Kato; Robyn J Barst; Anastasia Anthi; Michael R Robinson; Lori Hunter; Wynona Coles; James Nichols; Christian Hunter; Vandana Sachdev; Oswaldo Castro; Mark T Gladwin
Journal:  Br J Haematol       Date:  2005-08       Impact factor: 6.998

5.  Prevalence of pulmonary hypertension in patients with idiopathic pulmonary fibrosis: correlation with physiological parameters.

Authors:  D Papakosta; G Pitsiou; Z Daniil; M Dimadi; E Stagaki; A Rapti; K Antoniou; A Tzouvelekis; T Kontakiotis; S Tryfon; V Polychronopoulos; D Bouros
Journal:  Lung       Date:  2011-06-11       Impact factor: 2.584

6.  Impact of pulmonary hypertension on exercise performance in patients with interstitial lung disease undergoing evaluation for lung transplantation.

Authors:  Hilary F Armstrong; P Christian Schulze; Matthew Bacchetta; Wilawan Thirapatarapong; Matthew N Bartels
Journal:  Respirology       Date:  2014-05-06       Impact factor: 6.424

7.  Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis.

Authors:  Robert M Jackson; Marilyn K Glassberg; Carol F Ramos; Pablo A Bejarano; Ghazwan Butrous; Orlando Gómez-Marín
Journal:  Lung       Date:  2009-12-12       Impact factor: 2.584

8.  Pulmonary hypertension associated with lung transplantation obliterative bronchiolitis and vascular remodeling of the allograft.

Authors:  R Saggar; D J Ross; R Saggar; D A Zisman; A Gregson; J P Lynch; M P Keane; S Samuel Weigt; A Ardehali; B Kubak; C Lai; D Elashoff; M C Fishbein; W D Wallace; J A Belperio
Journal:  Am J Transplant       Date:  2008-07-28       Impact factor: 8.086

9.  Evaluation of recently validated non- invasive formula using basic lung functions as new screening tool for pulmonary hypertension in idiopathic pulmonary fibrosis patients.

Authors:  Maha K Ghanem; Hoda A Makhlouf; Gamal R Agmy; Hisham M K Imam; Doaa A Fouad
Journal:  Ann Thorac Med       Date:  2009-10       Impact factor: 2.219

Review 10.  [Interstitial lung diseases and pulmonary hypertension].

Authors:  H P Hauber
Journal:  Internist (Berl)       Date:  2009-09       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.